Oliver Witzke
Elite in Cytomegalovirus Infection

Oliver Witzke

Essen, NW, DE 
Elite in Cytomegalovirus Infection
Essen, NW, DE 
OverviewLocationsClinical Research

Overview

Oliver Witzke practices in Essen, Germany. Mr. Witzke is rated as an Elite expert by MediFind in the treatment of Cytomegalovirus Infection. His top areas of expertise are Cytomegalovirus Infection, Cytomegalic Inclusion Disease, Sepsis, Kidney Transplant, and Heart Transplant.

His clinical research consists of co-authoring 294 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 18 articles in the study of Cytomegalovirus Infection.

Gender
Male

Locations

Essen, NW 45147, Germany
Other Locations
Duisburg, NW, Germany
Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Open-Label Study to Evaluate the Efficacy and Safety of SCY-078 (Ibrexafungerp) in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment (FURI)
Open-Label Study to Evaluate the Efficacy and Safety of SCY-078 (Ibrexafungerp) in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment (FURI)
Enrollment Status: Completed
Publish Date: November 20, 2024
Intervention Type: Drug
Study Drug: Ibrexafungerp
Study Phase: Phase 3
Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Inhalation to Prevent ARDS in COVID-19 Pneumonia (GI-COVID)
Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Inhalation to Prevent ARDS in COVID-19 Pneumonia (GI-COVID)
Enrollment Status: Completed
Publish Date: May 10, 2023
Intervention Type: Drug, Other
Study Drug: Molgramostim
Study Phase: Phase 2
A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir
A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir
Enrollment Status: Completed
Publish Date: November 03, 2021
Intervention Type: Drug
Study Phase: Phase 3
View 2 Less Clinical Trials

293 Total Publications

Hemoptysis in a patient with MDR-tuberculosis: successful diagnosis with photon counting CT and embolization of a Rasmussen aneurysm.
Hemoptysis in a patient with MDR-tuberculosis: successful diagnosis with photon counting CT and embolization of a Rasmussen aneurysm.
Journal: Infection
Published: August 21, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Witzke's expertise for a condition
ConditionClose
View All 7 Advanced Conditions
View All 46 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile